Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Teva
Cantor Fitzgerald
Federal Trade Commission
Chinese Patent Office
McKesson
Deloitte
Merck
Mallinckrodt

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019763

« Back to Dashboard

NDA 019763 describes IFEX/MESNEX KIT, which is a drug marketed by Baxter Hlthcare and is included in one NDA. It is available from one supplier. Additional details are available on the IFEX/MESNEX KIT profile page.

The generic ingredient in IFEX/MESNEX KIT is ifosfamide; mesna. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ifosfamide; mesna profile page.
Summary for 019763
Tradename:IFEX/MESNEX KIT
Applicant:Baxter Hlthcare
Ingredient:ifosfamide; mesna
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 019763
Mechanism of ActionAlkylating Activity
Suppliers and Packaging for NDA: 019763
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
IFEX ifosfamide INJECTABLE;INJECTION 019763 NDA Baxter Healthcare Corporation 0338-3991 N 0338-3991-01
IFEX ifosfamide INJECTABLE;INJECTION 019763 NDA Baxter Healthcare Corporation 0338-3993 N 0338-3993-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength1GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Dec 30, 1988TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength3GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Dec 30, 1988TE:APRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength1GM/VIAL;100MG/ML
Approval Date:Oct 10, 1992TE:RLD:No

Expired US Patents for NDA 019763

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-002 Dec 30, 1988 ➤ Try a Free Trial ➤ Try a Free Trial
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-002 Dec 30, 1988 ➤ Try a Free Trial ➤ Try a Free Trial
Baxter Hlthcare IFEX/MESNEX KIT ifosfamide; mesna INJECTABLE;INJECTION 019763-003 Oct 10, 1992 ➤ Try a Free Trial ➤ Try a Free Trial
Baxter Hlthcare IFEX ifosfamide INJECTABLE;INJECTION 019763-001 Dec 30, 1988 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Medtronic
Merck
Dow
Mallinckrodt
Cerilliant
Farmers Insurance
Moodys
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.